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Human genetics: Methylation moves into medicine
Brian Hendrich
Two human genetic diseases have recently been shown
to be due to mutations in genes encoding proteins
involved in DNA methylation. The phenotypes of these
two diseases are surprisingly distinct from each other
and provide insights into the functions of DNA
methylation in mammals.
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The role of DNA methylation in mammalian development
has been a source of controversy for some time. Methyla-
tion of DNA, which takes place on the cytosine of CpG di-
nucleotides, is clearly required for development, because
mice lacking the maintenance methyltransferase gene
Dnmt1 die early in development [1]. It is also generally
agreed that the primary role of DNA methylation is to
silence transcription. The protein factors involved in
methylation are relatively well understood, as is the mecha-
nism by which DNA methylation brings about transcrip-
tional silencing. The disagreements arise, however, when it
comes to the question of exactly why methylation is
required. Is methylation responsible for programming
tissue-specific and stage-specific gene expression? Is
methylation present to limit unscheduled transcription
throughout the genome? Might methylation be present
solely to prevent the transcription of selfish DNA elements,
which are deleterious to the host? Or is some combination
of these possibilities closer to the truth? Finding the
answers to these questions has proven to be quite a difficult
nut to crack. A series of recent papers has brought the
‘awesome power of human genetics’ to bear upon these
questions, providing a few surprising answers. These
studies have revealed that mutations in genes encoding two
of the proteins known to be involved in DNA methylation
are responsible for different human genetic disorders.
ICF syndrome and DNMT3B
The ICF (immunodeficiency, centromere instability and
facial anomalies) syndrome is a rare, autosomal recessive
disorder in which patients suffer from immunodeficiency
caused by low immunoglobulin levels and mild facial
abnormalities [2]. Cultured lymphocytes from ICF
patients can show decondensation of the large heterochro-
matic, inactive regions of chromosomes 1, 9 and 16, often
resulting in the formation of abnormalities in chromosome
structure. The first clue that this might involve abnormal
DNA methylation came with the observation that these
chromosome abnormalities are very similar to those seen
when normal cells are treated with the demethylating
agent 5-azacytidine [2]. This led to the finding that the
sub-centromeric classical satellite DNA regions II and III,
which are highly methylated in normal cells, are grossly
undermethylated in ICF patients [3]. 
Genetic mapping of the ICF locus to the long arm of chro-
mosome 20 [4] narrowed the search for candidate genes,
and a very likely candidate emerged when the gene
encoding the de novo methyltransferase DNMT3β was
found to map to this same region [5]. So far, nine different
mutations in the DNMT3B gene have been identified
from eight different ICF families [6–8]. Xu et al. [8] have
also shown that a mutation found in one of their ICF
patients produces a protein with severely impaired de novo
methyltransferase activity. The spectrum of mutations
thus far reported is not predicted to result in a complete
lack of DNMT3β activity in any ICF patient, consistent
with the fact that complete DNMT3β deficiency in mice
results in prenatal lethality [7].
DNMT3β is one of two de novo methyltransferases having
overlapping functions in murine development, but is specif-
ically required for proper methylation of centromeric minor
satellite DNA in mice. This is somewhat different from the
situation in human cells, in which the hypomethylation
found in ICF patients is restricted to the sub-centromeric
classical satellite DNA, rather than the centromeric alpha
satellite DNA. Another difference between mice and
humans is that, whereas classical satellite DNA from ICF
patients appears mostly demethylated [3], murine embryos
lacking a functional Dnmt3b gene still show significant levels
of satellite methylation [7]. The differences between
DNMT3β function in mice and humans highlight the
importance of the new data from ICF patients in under-
standing more about methylation and human disease.
So, what can the range of clinical phenotypes in ICF syn-
drome tell us about the role(s) of DNA methylation in
humans? Given that the chromosomal abnormalities char-
acteristic of ICF syndrome occur only in lymphocytes,
might they somehow lead to the immunodeficiency that
is so devastating to sufferers of this syndrome? One might
expect the chromosome instability to lead directly to
immunodeficiency via aneuploidy and death of lympho-
cytes. But the immunodeficiency in ICF syndrome is due
to a general lack of immunoglobulins, and not to any cel-
lular deficiency. Perhaps methylation is required to
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prevent expression of a set of genes that interfere with
immunoglobulin production. Alternatively, methylation
may somehow be required for efficient recombination of
immunoglobulin genes in B-cell development and for the
prevention of interchromosomal recombination between
satellite DNA in lymphocytes. One unresolved question is
why the chromosome abnormalities are visible only in
lymphocytes and not in other cell types, given that the
undermethylation of satellite regions II and III is appar-
ently global in ICF syndrome [3]. DNA methylation may
be required for efficient replication of satellite DNAs, and
the short cell cycle of lymphocytes may not allow suffi-
cient time for complete replication of unmethylated satel-
lite DNA. This proposal seems somewhat counterintuitive
since, in general, hypomethylation correlates with early
replication. Perhaps some as yet unidentified lymphocyte-
specific factor binds to unmethylated satellite DNA, inter-
fering with condensation, recombination or replication.
The mild cranio-facial abnormalities in ICF syndrome are
reminiscent of those produced by chromosome aneu-
ploidy, and thus would be consistent with aberrant gene
regulation on a relatively large scale. Hypomethylation
may directly lead to aberrant gene regulation in this situa-
tion, or it may act via an indirect mechanism. For example,
Hansen et al. [6] suggest that the failure to properly
methylate satellite II and III sequences could alter chro-
matin organisation of the chromosomal domains in which
they reside, which in turn could affect the expression of a
set of neighbouring genes important for development via
so-called position effects. Xu et al. [8] suggest that meth-
ylated heterochromatin may nucleate the formation of
‘silencing foci’ — discrete regions of the nucleus that are
rich in methylated DNA and heterochromatin-binding
proteins that can silence genes in trans. This group pro-
poses that the lack of methylation in ICF syndrome may
interfere with the proper functioning of such foci, result-
ing in aberrant gene expression, which could lead to
immunodeficiency or other developmental abnormalities.
Does the discovery of the ICF syndrome gene have any
direct relevance for ICF patients? The initial impact will
certainly be on prenatal diagnosis for families at risk, once
more is known about the range of mutations that can give
rise to ICF syndrome. Hansen et al. [6] have shown that
the chromosomal phenotype can be rescued if ICF cells
are fused to hamster cells, indicating that application of a
wild-type copy of the DNMT3B gene can restore methyla-
tion of satellite DNA. The finding that at least one aspect
of the clinical phenotype can be reversed in vitro may be a
first step towards finding a treatment for ICF syndrome.
Rett syndrome and MECP2
Given that interfering with DNA methylation can give
rise to immunodeficiency, centromere instability and
facial abnormalities, might a similar phenotype result if a
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Figure 1
Disease-causing mutations in DNMT3β and
MeCP2. Schematic representations of the two
proteins are shown, with various protein motifs
indicated. (a) Mutations identified in DNMT3β
in ICF syndrome by Hansen et al. [6] are
indicated in blue, those identified by Okano
et al. [7] in green, and those identified by Xu
et al. [8] in red. One of the families studied by
Hansen et al. [6] was also studied by Okano
et al. [7]. The notation 53F/S refers to a one
base-pair insertion that gives rise to a
frameshift after codon 53, Ins800 refers to a
splicing error that results in a three amino acid
insertion, and ∆737–798 refers to a splicing
error resulting in a 62 amino acid deletion.
Methyltransferase motifs are shown as black
boxes within the catalytic domain. The grey
box indicates a sequence with weak homology
to motif VIII. N, amino terminus; C, carboxyl
terminus. The PWWP and C-rich domains are
amino-acid motifs of unknown function.
(b) Mutations in MeCP2 that give rise to Rett
syndrome. F/S refers to frameshifts, and a
change to the letter X represents a change to
a stop codon. Mutations identified by Amir
et al. [9] are indicated in red, while those
identified by Wan et al. [10] are indicated in
orange. The various functional domains of
MeCP2 are also labelled.
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gene encoding a protein that binds to methylated DNA is
mutated? The answer, at least in the case of one methyl-
CpG-binding protein, is unequivocally ‘no’. Mutations in
the gene encoding the transcriptional repressor protein
MeCP2 have been found to affect neural development in
humans, taking the form of Rett syndrome [9,10].
Patients suffering from this syndrome appear normal for
the first 6–18 months of life, but then begin to lose the
ability to speak or use their hands. This regression contin-
ues into autistic behaviour, ataxia, repetitive hand move-
ments, and microcephaly, and often involves breathing
abnormalities, seizures, eating problems, and growth
retardation [11]. In contrast to ICF syndrome, Rett syn-
drome is a relatively common disorder, occurring once
every 10,000–15,000 live female births [12] and is almost
never seen in males. The female specificity is due to the
fact that Rett syndrome is both X-linked and dominant,
meaning that female patients are heterozygous whereas
hemizygous males do not survive [13].
Although Rett syndrome was initially thought to be a neu-
rodegenerative disease, it is now recognised that the
degeneration is probably due to a defect that leaves the
developing brain unable to carry out the functions
required of it during postnatal growth [14]. Investigations
into the neuropathology of Rett syndrome have impli-
cated abnormal levels of neurotransmitters as being poten-
tially important for both the behavioural aspects of the
disease as well as the structural brain abnormalities includ-
ing microcephaly [14]. The idea that abnormal levels of
one or more neuroactive transmitters are to blame is very
appealing when one considers that the disease is caused
by mutations in the gene encoding MeCP2. This protein
has been shown to bind specifically to methylated DNA
and to be a potent transcriptional repressor that is particu-
larly abundant in the brain [15]. Might MeCP2-mediated
repression be directly responsible for controlling neuro-
transmitter levels in brain development? This idea seems
attractive, but at present it remains purely speculative.
Whereas a huge body of data has been generated on the
neuropathology of Rett syndrome in humans, the identifica-
tion of MECP2 as the gene responsible means that the focus
can now be shifted towards experimentation in model
organisms. It is already known that mice lacking a functional
Mecp2 gene die during embryogenesis [16], an observation
consistent with the presumed lethality of Rett syndrome in
males. Conditional knockout strategies can now be used to
model Rett syndrome in mice, which will allow theories
about its pathogenesis to be tested experimentally.
On average, only 50% of cells in females suffering from
Rett syndrome will express the mutant form of MeCP2,
assuming random X-chromosome inactivation. All Rett-
syndrome-associated mutations described thus far for
MeCP2 are expected to abolish its activity, because all are
predicted to interfere with protein folding or structural
integrity [9,10,17]. MeCP2 is an abundant chromosomal
protein that is detectable in many somatic tissues, but no
tissues other than the brain appear to be affected in Rett
syndrome. Thus, MeCP2 expression is apparently not
required in cells for them to give rise to a functioning
liver, kidney, germ cells, and so on. Similarly, mice
exhibiting a low level of chimerism for MeCP2 deficiency
are viable [16], indicating that in mice, as in humans,
MeCP2-deficient cells can contribute to adult tissues.
Why, then, is the brain apparently the only organ that does
not function properly when some cells fail to make a func-
tional MeCP2 protein? Perhaps the answer lies in the
nature of the organ in question. Whereas hepatic function
might not be noticeably impaired if a proportion of cells is
not performing properly, for example, brain function is
dependent upon a myriad of neuronal interconnections.
Thus, if one cell is not functioning properly, it might well
impair the function of several normal cells with which it
interacts, effectively throwing a spanner in the workings of
one or other region of the brain.
Lack of overlap
The function of DNMT3β appears to be to methylate
DNA, whereas MeCP2 binds to methylated DNA; thus
both proteins are involved in methylation-mediated tran-
scriptional silencing. If this is true, then why do muta-
tions in their respective genes give rise to diseases with
completely non-overlapping symptoms? This almost cer-
tainly is because our current understanding of the in vivo
functions of the DNMT3β and MeCP2 proteins, and of
DNA methylation in general, is woefully incomplete.
DNMT3β is only one of four potential cytosine-5 DNA
methyltransferases, and MeCP2 is but one of five poten-
tial methyl-CpG-binding proteins. Thus, the potential
for complexity and overlap of function is large. Linking
two different components of the DNA methylation
system to two very different human genetic diseases
does, however, represent two large steps forward in our
quest to answer that nagging question: why do we have
DNA methylation, anyway?
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If you found this dispatch interesting, you might also want
to read the April 1999 issue of
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Genetics & Development
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Centromere proteins and chromosome inheritance: a
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In vivo methods to analyze chromatin structure
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The full text of Current Opinion in Genetics &
Development is in the BioMedNet library at
http://BioMedNet.com/cbiology/gen
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